Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047908 | 1.00 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL19079535 | 0.76 | ALDH1A1 (0.59) | ALDH1A1TDP1 | |
| SCHEMBL20794273 | 0.76 | TRPA1 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL23021650 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TDP1 | |
| SCHEMBL16449045 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL24065157 | 0.75 | — | — | |
| SCHEMBL17428793 | 0.71 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL19483163 | 0.71 | ESR2 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL21075245 | 0.71 | ALDH1A1 (0.60) | ALDH1A1TDP1 | |
| SCHEMBL19454847 | 0.71 | ALDH1A1 (0.33) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885TDP1 1731/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | ALDH1A1 1155/4885TDP1 1731/4885 |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | ALDH1A1 2216/4885TDP1 2503/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885TDP1 1731/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | ALDH1A1 1155/4885TDP1 1731/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | ALDH1A1 1555/4885TDP1 4321/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885TDP1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.